Osteosarcoma Recurrent clinical trials at UC Cancer
2 research studies open to eligible people
open to eligible people ages 12-40
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: - Olaparib - Ceralasertib
open to eligible people ages 5 years and up
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Our lead scientists for Osteosarcoma Recurrent research studies include Kieuhoa Vo, MD, MAS.